This article is more than 5 years old. Information may no longer be current.
Omeros begins enrollment for phase 1/2 trial of novel cataract surgery treatment
SEATTLE — Omeros has begun enrolling patients in a phase 1/2 study of a product candidate to be used during cataract surgery, the company announced in a press release.
The treatment, called OMS302, is a proprietary combination of therapeutic agents, designed to pre-emptively block molecular signaling and biochemical cascades caused by surgical trauma, that may show clinical benefits during and after surgery, the release said. OMS302 may be added to standard irrigation solutions used in ophthalmic surgery and can be delivered directly to the eye.
The randomized, double-blind, vehicle-controlled, parallel-assigned clinical trial will evaluate the effect of OMS302 on intraoperative pupil dilation and on postoperative pain, discomfort and inflammation among a minimum of 60 patients undergoing cataract extraction with lens replacement.